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Abstract
Herpes zoster (shingles) can be a painful and debilitative disease followed by the
unwanted side effect of postherpetic neuralgia. Herpes zoster is an effect of the varicella-zoster
virus (VZV) which also causes the commonly known childhood illness of chicken pox. The
reactivation of this disease results in the painful blistering lesions of herpes zoster that requires
management and primary prevention strategies through the herpes zoster vaccine
(Zostavax). This literature review focuses on those different strategies of management and the
primary prevention through vaccination. The foundation of this review was determined by an
outpatient visit conducted at the clinical education center where, on the exam, a 52-year-old male
presented with a rash on his face. It was identified that the patient was uninformed of the
prevention and management of postherpetic trigeminal neuralgia. A systematic search of the
primary prevention in the management of postherpetic trigeminal neuralgia was conducted. Four
different databases, including CINAHL, PubMed, Google Scholar and MedScape were searched
concentrating on studies completed within the last ten years. The bulk of the appropriate articles
obtained were randomized controlled trials, all of which demonstrated that acknowledgment of
primary and secondary prevention is key in the management of postherpetic trigeminal neuralgia.
Keywords: postherpetic trigeminal neuralgia, primary prevention, shingles, vaccination
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Background
In 2008, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended
that eligible Americans 60 years of age and older should receive the shingles vaccine, also
known as Zostavax (Centers for Disease Control and Prevention, 2015). A recent study
conducted by the CDC showed the vaccine could reduce the rate of shingles by 51% with a 67%
reduction in postherpetic neuralgia (CDC, 2015). The Zostavax vaccine is a live, attenuated
vaccine that is not recommend with patients who have a weakened immune system (Merek &
Co., 2006). The Food and Drug Administration (FDA) approved the vaccine for people who are
50 years of age or older (Merek & CO., 2006). However, the CDC does not recommend the
routine vaccine in people who are 50-59 years of age, as the protection of the vaccine only lasts
for 5 years, so people who receive the vaccine may not be protected later on in life when they
have an increased risk for developing shingles, causing an increased risk for complications
(CDC, 2015).
In regards to the robust studies shown in regards to the positive outcomes from the
vaccine, most Medicare and private insurance drug plans will cover the administration of the
vaccine (CDC, 2015). The vaccination is not recommended on the adult immunization schedule
for adults 50-59 years of age, most insurance drug plans do not provide a benefit for shingles
vaccination for this group of people (CDC, 2015). However, the following case report will
discuss a situation in which the zoster vaccine could have prevented unwanted complications of
the varicella virus. This literature review will discuss postherpetic neuralgia and effective
management strategies along with primary prevention.
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Case Report
For the purpose of anonymity in this specific case report the patient will be referred to as
David (DJ). David is a 52-year-old male who presented to the clinical education center with a
chief complaint of a rash on his face. He stated the area around his left eye has been very painful
and itchy. He also noticed that his vision has been blurry in the left eye since Wednesday
February 3rd, 2016 (2 days ago). No history or physical information was on file for this patient
and was all obtained during this visit.
History
David did not have an extensive medical or surgical history. He does not have any known
environmental or drug allergies. He stated that he is unsure if his immunizations are currently up
to date but does remember having the chicken pox when he was a child. He said, “I haven’t been
to the doctor in many years.” His family history was thoroughly discussed resulting in no
pertinent family history such as cancer, cardiovascular disease, diabetes or clothing disorders.
He is an accountant who regularly sits at his desk and says he is quite busy this time of year,
which has caused an increase in stress. He says he tries to eat a healthy diet, exercise regularly
and drinks at least 2 Liters of water per day. He denied any recreational drug, tobacco, and
smokeless tobacco use. He drinks about one beer per day.
Review of Systems
During his exam a review of systems were completed, the following shows the abnormal
findings: positive for left eye pain described as burning, throbbing and stabbing in nature with
itching and blurred vison. Positive for anxiety related to increased stress at work related to the
current tax season. Positive for erythema and vesicular rash around left eye. He did not have a
fever, cough, nausea or vomiting. He has no prior history of trauma to the head or eye.
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Physical Exam
Vital signs revealed a blood pressure of 152/97 mmHg, pulse 76 beats per minute,
temperature 97.4 degrees Farenheight, weight of 140 pounds, and height 5 foot 8 inch. The
physical examination abnormal findings are as follows: visible patchy erythema and grouped
herpetiform clear vesicles to dermatomal mandibular nerves V2 and V3 that are tender upon
palpation. All other physical examinations were unremarkable. Heart sounds S1, S2 with regular
rate and rhythm. Lung sounds are clear throughout lung fields. Pulses 2+ in all four extremities
along with carotid pulses 2+ bilaterally without bruits. The testing of cranial nerves I through
XII showed no deficits except for cranial nerve II which is due to the blurriness in vision. He is
alert and oriented x 3. No lymphadenopathy, swelling or redness around throat. PERRLA, EOM
intact.
Management of Care
David’s history and physical examination concluded the diagnosis of trigeminal shingles.
Further diagnostic testing was not appropriate due to the findings revealed in David’s history and
physical examination. D.J. was unaware of the shingles vaccine along with the postherpetic pain
that can accompany this diagnosis. David was prescribed and instructed to take Acyclovir
(Zovirax) 800 mg orally every four hours, five times daily for seven days; Gabapentin
(Neurontin) 300 mg orally four times per day and Ultram (Tramadol) 100 mg orally every four to
six hours as needed for pain. It was recommended he establish with a primary care provider to
discuss high blood pressure, immunizations and other screening tests (colonoscopy and PSA) to
prevent and reduce the risk of illness.
David’s case shows that primary prevention of the varicellovirus is significant in the
management of postherpetic neuralgia. Healthcare providers must be attentive when caring for
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young children with chickenpox and educating the parents that the child is at increased risk for
Varicella Zoster Virus (VZV) when they are older. Therefore, it is the responsibility of the

healthcare provider to practice preventative care and inform each patient and his or her family
that a medical history of chickenpox predisposes the patient to VZV. This ensures a limited
possibility of complications related to the varicella virus later in life. This leads to the importance
of management of VZV to prevent further complications of postherpetic neuralgia as indicated in
David’s case. Thus, a literature review was completed to determine the proper management and
primary prevention strategies related to David’s diagnosis.
Search Strategies
The purpose of this literature review was to demonstrate the best pharmacological options
and primary prevention secondary to herpes zoster are significantly beneficial in the management
of postherpetic neuralgia. As previously described, in regards to the robust studies shown in
regards to the positive outcomes from the vaccine. David is a 52-year-old male who was unaware
that having chickenpox as a child made him more susceptible to herpes zoster. Therefore, the
main priority of the search strategy focused on herpes zoster primary prevention and
management of postherpetic neuralgia.
The literature originated with an electronic search to obtain applicable literature
associated to the topic. The search engines used were obtained through the University of North
Dakota Harley French Library of the Health Science student access library website. I utilized
four different search engines Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PubMed, Google Scholar and MedScape.
The first search engine used was CINAHL in which “postherpetic neuralgia” AND
“management” were used in the search fields. This initial search yielded 13 results in which the
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search was then narrowed down to publications within the last ten years. This reduced the search
results to 8 articles and of those articles 4 were determined to be appropriate literature for the
clinical topic. Other search terms were included such as: trigeminal neuralgia, prevention of
herpes zoster and herpes zoster vaccine. All of these terms yielded similar results narrowing the
search.
The second search engine used was PubMed. The initial search keywords were
“trigeminal shingles and postherpetic neuralgia” along with a limited search to studies published
within the last ten years. This search provided 33 results. Two of the titles in the results were
similar to the CINAHL search and were quickly excluded. Based off the remaining results, the
articles were reviewed for specific titles, level of research, and interest related to the research
objective. It was determined that five more articles were clinically relevant.
The last two search engines that were utilized were Medscape and Google Scholar
keywords were “trigeminal neuralgia and herpes zoster” which results in 7 reviewed articles.
Literature Review
It is estimated that over one million new herpes zoster episodes occur each year in the
United States, resulting in 1 in 3 people developing herpes zoster (Weaver, 2007). Reactivation
of the varicella zoster virus (the virus that is also responsible for causing chickenpox) produces
shingles. This is a very painful, blistering skin rash. For years the varicella zoster virus can be
dormant in the spinal dorsal root ganglia and sensory cranial nerves without producing
symptoms until cellular immunity to Varicella zoster virus (VZV) declines with
immunosuppression, stress, trauma or aging (Nalamachu and Morley-Forster, 2012). VZV
affects the dermatomal areas in the body. Once compromised, the reactive virus moves in the
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sensory nerves to the skin (Sampathkumar, Drage, and Martin, 2009). As soon as this has
occurred individuals commonly seek help and are diagnosed with the VZV.
Background
The incidence of individuals age 60 years and older is 11.12 cases per 1000 patient years
(Weaver, 2007). The incidence is relatively low amongst people aged 40 years or younger,
ranging from 0.9 to 1.9 cases per 1000 patient-years, however it begins to rise from then on
(Weaver, 2007). The incidence amongst individuals aged 40 to 49 years occurs in 2.5 per 1000
patient-years among. The incidence amongst those aged 50 to 59 years is 3.8 cases per 1000
patient-years (Weaver, 2007). The incidence amongst individuals aged 60 to 69 years is 6.1 cases
per 1000 patient-years (Weaver, 2007). The incidence amongst individuals aged 70 to 79 years is
8.5 cases per 1000 patient-years (Weaver, 2007). The incidence amongst individuals aged 80
years and older is 9.4 cases per 1000 patient-years with over sixty percent of all cases occurring
in individuals over 50 years of age (Weaver, 2007). The incidence and prevalence of the VZV
proves to be a problem and results in manifestations that affect the central nervous system.
Herpes zoster of the trigeminal (V) nerve is divided into herpes zoster of the ophthalmic
(V1), maxillary (V2) and mandibular (V3) nerve correspondingly. Herpes zoster ophthalmicus
(HZO) arises when VZV invades the gasserian ganglion, which accounts for 10-15% of all zoster
cases and is five times more likely to occur than the maxillary (V2) and mandibular (V3) types
(Li, Lan, and Zhang, 2015). The appearance of a trigeminal herpes zoster is similar to other oral
entities and we need to be aware of the differential diagnosis and definitive treatment modalities
(Li, Lan, and Zhang, 2015). Common complications often lead to differential diagnosis
associated with VZV.
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The most common complication from the herpes zoster is postherpetic neuralgia. It
occurs in nearly 30% of individuals 50 years of age or older (Fashner and Bell, 2011).
Reactivation of the varicella-zoster virus in the basal ganglia extinguishes the nerves, leading to
increased pain in the affected dermatome. Risk factor for postherpetic neuralgia include: history
of prodromal pain, women, older adults, history to moderate to severe rash, moderate to severe
acute pain with rash, and ophthalmic involvement (Fashner and Bell, 2011). Postherpetic
neuralgia can persevere from 30 days to six months or more after the skin lesions have healed,
but thankfully, in most cases it resolves spontaneously on its own (Fashner and Bell, 2011). Due
to the variation in the severity of the disease, VZV can have many different management
strategies.
Management
The main goal with the management of trigeminal neuralgia secondary to herpes zoster is
the reduction of pain in herpes zoster (Tyring, 2007). All individuals being seen should have a
medical and psychosocial history evaluation and focused physical examination performed to
confirm the proper diagnosis and treatment of postherpetic trigeminal neuralgia (Tyring, 2007).
Early referrals to an ophthalmologist is essential for all individuals with ocular involvement.
Older adults that may have cognitive impairment, major life events or socially isolated could
influence treatment compliance (Tyring, 2007). Assessing the individual for anxiety/depression
is also very important as it could complicate HZ treatment (Tyring, 2007).
First Line Therapy. For the first 72 hours after the onset of rash, the US FDA has
approved Acyclovir (800 mg 5 times daily for 7–10 days), Famciclovir (500 mg 3 times daily for
7 days), and Valacyclovir (1000 mg 3 times daily for 7 days) for the management of HZ (Quan,
Hammack, Kittelson, and Gilden, 2006). These antiviral agents are phosphorylated by viral
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thymidine kinase and cellular kinases to a triphosphate form that inhibits viral duplication (Quan,
Hammack, Kittelson, and Gilden, 2006). First line treatment issued by the American Academy of
Neurology, the International Association for the Study of Pain and the European Federation of
Neurological Societies that are utilized in the management of postherpetic neuralgia secondary to
herpes zoster are tricyclic antidepressants (TCA), pregabalin, gabapentin and topical lidocaine
5% patch (Baron, 2009). Because of safety efficacy, disadvantages the following are considered
second line treatment such as opioids, tramadol, capsaicin cream and the capsaicin 8% (Argoff,
2011). TCA’s increase serotonin and norepinephrine levels which block the sodium channel and
alpha-adrenergic receptors which decreases the pain pathway, these include amitriptyline,
nortriptyline, imipramine (Baron, 2009). The efficacy of tricyclic antidepressants in the treatment
of PHN pain is well established (Argoff, 2011). Finnerup, Otto, McQuay, Jensen, and Sindrup
(2005) completed a systematic review, with the combined number of desired to treat with
amitriptyline, desipramine, or nortriptyline to acquire a single individual with a 50% decrease in
PHN pain compared to the 2.5% in the placebo. Although proven to decrease PHN, TCA’s may
not be more applicable option for all individuals with depression, social isolation, or
cardiovascular risks (Saarto and Wiffen, 2010). Pregabalin and Gabapentin also known as,
anticonvulsants disrupt calcium channel blockers, hindering central pain pathways (Saarto and
Wiffen, 2010). In the Cochrane Database of Systematic Reviews, the goal was to decrease PHN
pain by 50% with gabapentin and pregabalin 300–600 mg (Saarto and Wiffen, 2010). The
lidocaine 5 % patch blocks sodium channels decreasing ectopic impulses impaired by major
afferent pain receptors (Moore, Wiffen, Derry, Toelle, and Rice, 2014). The prescribing
recommendations for first-line medications will be discussed next.
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The starting dose for TCAs is 25 mg at bedtime, increasing by 25 mg/day every 3- 7 days
as tolerated, the maximum dose is 150 mg/day; if blood concentration of active medication and
its metabolite is <100 mg/L continue titration with caution. The duration of this medication
should be 6-8 weeks with at least 2 weeks at maximum tolerated dosage (Dworkin, O'Connor,
Audette, Baron, Gourlay, Haanpää, & Turk, 2010). SSNRIs (Duloxetine) starting dose is 30 mg
once daily increasing to 60 mg daily after the first week with a maximum dose of 60 mg per day
for 4 weeks (Dworkin & et, al., 2010). Another SSNRI (Venlafaxine) starting dose is 37.5 mg
once or twice daily and then increasing to 75 mg daily with a maximum dose of 225 mg per day
for 4-6 weeks (Dworkin & et, al., 2010). Calcium channel a2 -d ligands (Gabapentin) starting
dose is 100-300 mg at bedtime or 100-300 mg 3 times daily increasing by 100-300 mg 3 times
daily every 1-7 days as tolerated with a maximum dosage of 3600 mg/day with a duration of 3-8
weeks for titration plus 2 weeks at maximum dose (Dworkin & et, al., 2010). Another Calcium
channel a2 -d ligands (Pregabalin) starting dose is 50 mg 3 times daily or 75 mg twice daily as
tolerated increasing to 300 mg/day after 3-7 day, then by 150 mg/day every 3-7 days as tolerated
with a maximum dose of 600 mg/day for four weeks (Dworkin & et, al., 2010). The 5%
lidocaine patch starting dose is one patch every 12 hours with a maximum of 3 patches daily for
three weeks (Dworkin & et, al., 2010). These pharmacological recommendations are of great
assistance along with implementation of primary prevention when caring for patients who are
experiencing postherpetic neuralgia.
Primary Prevention
In a prevention study pertaining to shingles, In a three year trial there were 38,000
individuals who were 60 years of age or older who were randomized to management of their
herpes zoster with either the herpes zoster vaccine or placebo (Sampathkumar, Drage, and
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Martin, 2009). The herpes zoster vaccine reduced the incidence of herpes zoster infection versus
placebo by nearly 50% with 107 individuals with PHN (Sampathkumar, Drage, and Martin,
2009). The vaccine significantly reduced the incidence of PHN versus placebo by almost twothirds (Sampathkumar, Drage, and Martin, 2009). The study also showed that the vaccine was
well tolerated with serious side effects equal to that of the placebo (Sampathkumar, Drage, and
Martin, 2009). The analysis showed that the herpes zoster vaccine was most cost-effective for
patients 70 years of age or older (Sampathkumar, Drage, and Martin, 2009). Additionally, the
vaccine was more cost-effective in women than in men, as women are proven to be more
disproportionately affected by herpes zoster and PHN compared with men (Sampathkumar,
Drage, and Martin, 2009). The immunization can be administered to anyone regardless of history
of varicella virus infection or herpes zoster.
The Centers for Disease Control and Prevention Advisory Committee on immunization
practices now advocates the regular use of the herpes zoster vaccine in immunocompetent
patients 60 years of age or older. Current guidelines for the treatment of PHN emphasize
pharmacological management as well (Sampathkumar, Drage, and Martin, 2009).
Conclusion
The review of literature delivered a strong point that administration of the herpes zoster
vaccine is effective in the prevention of postherpetic neuralgia. If David would have been
educated on the vaccine recommendations, he would have a 2/3 chance that he would not
develop PHN. There are many points that were observed through the literature review and are
important to take note in regards to David’s case. Key points and findings related to this research
are:
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As a standard of care assess patients’ immunization status at every clinical encounter and
strongly recommend the Zostavax vaccine for people over the age of 60.



Implement reminders that can be generated through an electronic health record or
immunization registry that notes when a patient needs to be vaccinated or qualifies for the
Zostavax vaccine.



Give patients’ a Zostavax vaccine questionnaire to complete at the time they check-in for
their appointment to help identify any vaccines that they may need based on any changes
in their medical condition.

Overall, herpes zoster is a manageable virus. The current pharmacological recommendations
that were discussed assist with the starting dose, maximum dose, and duration of medications in
the management of postherpetic neuralgia. It is important to start patients on a TCA and SSNRI
to help manage postherpetic neuralgia pain. The most effective strategy is done by primary
prevention through the Zostavax vaccine as it decreases PHN.
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